Payment overview · 2025
General Payments
$330.75
8 reported records · 4 companies
Healthcare provider profile · identity verified
Wan Yao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MONTEREY PARK, CA · NPI 1518951649
Verified facts
What the public records show
CMS Open Payments records show Wan Yao, M.D. received $330.75 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 80.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synjardy by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $264.60 | 80.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.53 | 6.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.85 | 6.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.77 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $175.00 | 1 |
| Food and Beverage | $155.75 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.60 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.85 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 262 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
83 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1130 | 291 |
| Amlodipine Besylate | Amlodipine Besylate | 1114 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 195 |
| Vascepa | Icosapent Ethyl | 469 | 76 |
| Raloxifene Hcl | Raloxifene Hcl | 392 | 100 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 368 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 98 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 264 | 142 |
| Jardiance | Empagliflozin | 262 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 58 |
| Losartan Potassium | Losartan Potassium | 221 | 61 |
| Farxiga | Dapagliflozin Propanediol | 213 | 43 |
| Montelukast Sodium | Montelukast Sodium | 210 | 93 |
| Ezetimibe | Ezetimibe | 190 | 61 |
| Icosapent Ethyl | Icosapent Ethyl | 189 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 43 |
| Linzess | Linaclotide | 156 | 31 |
| Azelastine Hcl | Azelastine Hcl | 152 | 74 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 147 | 89 |
| Famotidine | Famotidine | 136 | 59 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 130 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 130 | 40 |
| Metformin Hcl | Metformin Hcl | 125 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 120 | 31 |
| Glimepiride | Glimepiride | 113 | 26 |
| Gabapentin | Gabapentin | 112 | 44 |
| Finasteride | Finasteride | 109 | 34 |
| Meloxicam | Meloxicam | 102 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 22 |
| Glipizide Er | Glipizide | 86 | 25 |
| Atenolol | Atenolol | 84 | 19 |
| Allopurinol | Allopurinol | 83 | 22 |
| Prolia | Denosumab | 83 | 48 |
| Lidocaine | Lidocaine | 82 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 81 | 51 |
| Omeprazole | Omeprazole | 80 | 30 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 77 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 71 | 51 |
| Nifedipine Er | Nifedipine | 71 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 64 | 41 |
| Hydrocortisone | Hydrocortisone | 58 | 26 |
| Silodosin | Silodosin | 55 | 12 |
| Carvedilol | Carvedilol | 54 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 26 |
| Ztlido | Lidocaine | 54 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 53 | 30 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Azithromycin | Azithromycin | 51 | 50 |
| Celecoxib | Celecoxib | 51 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 15 |
| Mupirocin | Mupirocin | 50 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 31 |
| Triazolam | Triazolam | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Lisinopril | Lisinopril | 36 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 32 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 11 |
| Febuxostat | Febuxostat | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 25 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Benicar | Olmesartan Medoxomil | 29 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 22 |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 16 |
| Fluocinonide | Fluocinonide | 25 | 17 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 21 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 16 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Benzonatate | Benzonatate | 22 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Rapaflo | Silodosin | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 17 |
| Furosemide | Furosemide | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Baclofen | Baclofen | 15 | 11 |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.75 · 8 records | Amgen Inc. | INGREZZA, JARDIANCE, OTEZLA, PROLIA, REPATHA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error